Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Non-current Assets
All assets not expected to be converted to cash within one year.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 602.0% from a year ago
Total non-current assets stood at $2.11M at the end of Q1 FY2026, up 602.0% from a year earlier and down 3.5% from the prior quarter. Over 3 fiscal years it compounded at +65.2% a year.
Context
- Total non-current assets amounted to 3.1% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +602.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 2.19M USD
- Year-over-year change
- +918.6%
- 4-year CAGR
- +29.2%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.19M | +918.6% |
| FY2024 | 2024-12-31 | 215K | -67.1% |
| FY2023 | 2023-12-31 | 653K | +34.4% |
| FY2022 | 2022-12-31 | 486K | -38.2% |
| FY2021 | 2021-12-31 | 786K | — |
Total Non-current Assets vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +602.0% is the highest of 10, against a peer median of -16.4%.
- Total non-current assets amounts to 3.1% of total assets for FBRX, versus a peer median of 10.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $136.19M USD | -31.6% | +2.7% | 36.6% | |
| Mar 2026 | $105.39M USD | -30.0% | -18.5% | 37.0% | |
| Mar 2026 | $24.83M USD | -40.4% | -24.1% | 10.4% | |
| Mar 2026 | $22.02M USD | -16.4% | -9.9% | 14.1% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $6.49M USD | -10.0% | -18.2% | 28.6% |
| Mar 2026 | CHF 4.72M CHF | +13.8% | -11.3% | 5.4% | |
| Mar 2026 | $2.11M USD | +602.0% | +65.2% | 3.1% | |
| Mar 2026 | $1.83M USD | -12.7% | -29.0% | 3.7% | |
| Mar 2026 | $914K USD | -64.4% | -41.3% | 0.6% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $391.84K USD | +67.1% | — | 4.4% |
| Peer median (excluding FBRX) | — | -16.4% | -18.3% | 10.4% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.